Research

In this paper, the authors report three patients infected with SARS-CoV-2 who developed generalised myoclonus. Two men and one woman (aged 63 to 88) presented with mild hypersomnia and generalised myoclonus following onset of the so-called “inflammatory” phase of COVID-19 infection.

In this article, just published in Lancet, the authors report an analysis of multinational registry data on the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19.

In this article, just published in the New England Journal of Medicine, Beigel et al. conducted a double-blind, randomised, placebo-controlled trial of intravenous remdesivir in adults hospitalised with Covid-19 with evidence of lower respiratory tract involvement.

Is ambulatory (at home) polysomnography valid and reliable on a scientific basis?

For June 2020, we have selected: Mao L. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China JAMA

In this paper, Dinkin et al., describe two patients who developed cranial neuropathies within days of respiratory symptoms related to SARS-CoV-2 infection and were found to have abnormal perineural or cranial nerve findings on MRI.

In this study recently published in Radiology, the authors describe brain magnetic resonance imaging findings in patients in the intensive care unit with COVID-19 pneumonia.

In this paper, the authors report the case of a 40-year-old man who developed acute brainstem dysfunction 3 days after hospital admission with symptoms of COVID-19 infection.

In order to inform the neurological community and patients, the Italian Association of the Peripheral Nervous System (ASNP), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Society of Neurology (SIN) have developed a joint document to guide best practice for managing patients with immune-mediated neuropathy during the global spread of COVID-19.

This paper, recently published in Revue Neurologique, summarises recommendations for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network (FILNEMUS).

In this consensus statement recently published in Neuro-Oncology, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGG) during the COVID-19 pandemic.

Most medical centres are postponing elective procedures and deferring non-urgent clinic visits to conserve hospital resources and prevent spread of COVID-19.

In this review, the authors explore the risk of COVID-19 in PD patients in terms of susceptibility to severe disease, impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak.

In this correspondence recently published in Lancet Neurology, the authors report the results of the pilot phase of an investigation of effects of COVID-19 among Italian people with multiple sclerosis, based on a core dataset collected from treatment providers through a specifically designed web-based case report form.

In this paper, the authors report a patient treated with natalizumab for relapsing-remitting MS who developed COVID-19 and recovered in a few days without complications.